| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3339918 | Allergologia et Immunopathologia | 2012 | 10 Pages |
Abstract
There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
J. Sanchez, R. Ramirez, S. Diez, S. Sus, A. Echenique, M. Olivares, R. Cardona,